SLSSELLAS Life Sciences Group, Inc.
Price
+615%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
In the company’s own words · 10-K filed Mar 19, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jul 27, 2026As previously disclosed, the Company commenced a binding arbitration against 3D Medicines, Inc. (“3D Medicines”), administered by the Hong Kong International Arbitration Centre (“HKIAC”)Earnings release · Form 8-K
- Jun 25, 2026Compensatory Arrangements of Certain Officers On June 24, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) entered into (i) an amendment (the “Stergiou Amendment”) to that certain employment agreement effective as of July 1, 2019 (the “Stergiou Employment Agreement”), by and between the Company and Dr. Angelos …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.